US Broker Ratings

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Biotechnology Growth with 36% Potential Upside

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a dynamic player in the biotechnology sector, has been making waves with its innovative approach to treating rare and orphan diseases. Headquartered in Foster City,..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a 22.66% Potential Upside in CNS Therapeutics

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a prominent player in the biopharmaceutical industry, has carved a niche with its focus on developing and commercializing medicines targeting central nervous system (CNS) disorders..

CRISPR Therapeutics AG (CRSP) Stock Analysis: A Biotech Powerhouse with a 96.41% Potential Upside

CRISPR Therapeutics AG (NASDAQ: CRSP) stands at the forefront of biotechnology innovation, carving a niche in the dynamic sector with its revolutionary CRISPR/Cas9 gene-editing platform. With a current market cap..

SpringWorks Therapeutics, Inc. (SWTX) Stock Analysis: Unveiling the Biotech Innovator’s Growth Potential

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) stands as a noteworthy player in the biotechnology sector, with a market capitalization of $3.53 billion. This commercial-stage biopharmaceutical company is headquartered in Stamford, Connecticut,..

Privia Health Group, Inc. (PRVA) Stock Analysis: A 32.59% Upside Potential Awaits Investors

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector with a focus on health information services, presents an enticing opportunity for investors. With a market capitalization..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A Potential 142% Upside in the Biotech Sector

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) presents a compelling opportunity for investors looking to tap into the burgeoning biotechnology sector, particularly in the niche field of rare and ultra-rare genetic diseases...

Immunovant, Inc. (IMVT): Investor Outlook on a Promising 180% Upside in the Biotech Sector

Immunovant, Inc. (NASDAQ: IMVT) is capturing investor attention with its compelling potential upside of 180.08%, according to recent analyst ratings. As a clinical-stage biotechnology company, Immunovant is focused on developing..

Arcellx, Inc. (ACLX) Stock Analysis: Exploring a 73.53% Upside Potential in Biotech

Arcellx, Inc. (NASDAQ: ACLX), a promising player in the biotechnology sector, is drawing significant attention from investors with its impressive potential for growth and innovation in the field of immunotherapies...

Alvotech (ALVO) Stock Analysis: Unveiling a 92.72% Potential Upside in the Biosimilar Market

For investors seeking opportunities in the healthcare sector, Alvotech (NASDAQ: ALVO) presents a compelling case with a notable potential upside of 92.72%. This Luxembourg-based company is carving out a niche..

Scholar Rock Holding Corporation (SRRK) Investor Outlook: A 54.58% Potential Upside Beckons

Scholar Rock Holding Corporation (NASDAQ: SRRK), a dynamic player in the biotechnology sector, has piqued investor interest with its promising pipeline in the healthcare industry. Headquartered in Cambridge, Massachusetts, this..

Metsera, Inc. (MTSR) Stock Analysis: Exploring a Promising 86% Upside in Biotechnology

Metsera, Inc. (MTSR), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to tackling obesity and related disorders. Headquartered in New York, Metsera focuses..

Amedisys Inc (AMED) Investor Outlook: Navigating Market Challenges in the Healthcare Sector

Amedisys Inc (AMED), a prominent player in the healthcare sector, continues to attract attention from investors seeking opportunities in the medical care facilities industry. With a market capitalization of $3.19..

PROCEPT BioRobotics (PRCT) Stock Analysis: A 27% Potential Upside Amid Robust Revenue Growth

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) has been a standout performer in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $3.34 billion, this U.S.-based company..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Exploring a 15.86% Upside Potential in the Eye Health Market

Bausch + Lomb Corporation (NYSE: BLCO) stands as a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $4.42 billion,..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 32.62% Upside Potential in Rare Disease Biotech

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stands at the forefront of biotechnology with a focus on rare neuroendocrine diseases. As a commercial-stage biopharmaceutical entity, Rhythm’s market capitalization has soared to $4..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Strong Buy Ratings and 16.75% Upside Potential

Merit Medical Systems, Inc. (NASDAQ: MMSI), a key player in the healthcare sector, has captured the attention of investors with its robust performance and promising growth prospects. Specializing in the..

RadNet, Inc. (RDNT) Stock Analysis: A 29% Upside Potential in the Healthcare Diagnostics Sector

RadNet, Inc. (NASDAQ: RDNT) is making waves in the healthcare sector, particularly within the diagnostics and research industry. With its expansive network of outpatient diagnostic imaging services in the United..

Telix Pharmaceuticals Limited (TLX) Stock Analysis: Exploring a 41.73% Upside in the Biotech Space

Telix Pharmaceuticals Limited (TLX), an innovative player in the biotechnology sector, is making waves with its promising pipeline of radiopharmaceutical products aimed at treating cancer and rare diseases. Headquartered in..

Elanco Animal Health (ELAN): Investor Outlook with a 7.63% Potential Upside

Elanco Animal Health Incorporated (NYSE: ELAN) presents an intriguing opportunity for investors in the healthcare sector, specifically in the niche of animal health. As a company with a significant global..

Guardant Health, Inc. (GH) Stock Analysis: Unlocking a 21% Potential Upside in Precision Oncology

Guardant Health, Inc. (NASDAQ: GH), a pioneering force in the healthcare sector, specifically within the Diagnostics & Research industry, is captivating investor interest with its formidable growth potential. With a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds